ArticleMetabolic brain disease2026
Vascular endothelial growth factor (VEGF)-related blood flow regulation and anti-inflammation in the protection of Danzhu Fuyuan Granules against cognitive impairment.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Vascular dementia (VaD) is driven by chronic cerebral hypoperfusion and neuroinflammation, yet effective interventions capable of acting on multiple pathological processes remain limited. Danzhu Fuyuan Granules (DFG) has been used clinically for cognitive impairment, but its therapeutic mechanisms remain poorly elaborated. Bilateral carotid artery stenosis (BCAS)-induced VaD was validated by behavioral evaluation, with cerebral blood flow (CBF), regional homogeneity (ReHo), and fractional anisotropy (FA) assessed by magnetic resonance imaging (MRI), and neuronal and white matter damage examined by histological staining. Serum constituents of DFG were identified using UHPLC-Q-TOF-MS, and potential therapeutic mechanisms were predicted through network pharmacology. RT-PCR, molecular docking, western blotting (WB), and ELISA were used to identify the potential targets. DFG significantly ameliorated cognitive impairment in mice with VaD. MRI showed restored CBF and enhanced ReHo, consistent with histological evidence that DFG attenuated neuronal loss and white-matter damage. Forty serum constituents and 54 putative targets were identified, with 10 core proteins highlighted by network analysis. RT-PCR validated 22 genes linked to angiogenesis, inflammation, oxidative stress, and apoptosis. Molecular docking suggested strong binding of key constituents to hub targets such as KDR and SRC. DFG also restored VEGF family expression and suppressed inflammatory mediators. DFG could improve cognitive function and attenuate neuronal loss and white matter lesions in VaD, potentially by influencing VEGF-related blood flow regulation and anti-inflammation.
Indexed as
Identifiers
41984273What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.